Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.-4. (*Cancelled*).

5. (*Currently amended*) A method of reducing the risk of insulin-induced ~~preventing~~ hypoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering a basal replacement dose of glucagon to a patient ~~and~~ who is not suffering hypoglycemic symptoms ~~which method comprises administering glucagon to said patient in an amount therapeutically effective for the prevention of hypoglycemia~~.

6. (*Original*) The method of claim 5, wherein said glucagon is administered simultaneously with, or within one minute to four hours after said patient has last been administered insulin.

7. (*Cancelled*).

8. (*Currently amended*) The method of claim 5 ~~2~~, wherein ~~said insulin is administered parenterally and~~ said glucagon is administered ~~by a route of administration selected from the group consisting of oral administration, ocular administration, nasal administration, pulmonary administration, parenteral administration, and transdermal administration~~ parenterally by a subcutaneous, intramuscular, or intravenous route.

9. (*Currently amended*) The method of claim 5 ~~8~~, wherein the patient has a blood glucose level of from 70 - 110 mg/dL ~~said glucagon is administered transdermally~~.

10. (*Original*) The method of claim 8, wherein said glucagon is a glucagon with a longer duration of action.

11. (*Cancelled*).

12. (*Original*) The method of claim 8, wherein said glucagon is contained in a liposomal formulation.

13. (*Original*) The method of claim 8, wherein said glucagon is contained in a microsphere.

14.-17. (*Cancelled*).

18. (*New*) The method of claim 5 wherein the basal replacement dose of glucagon results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 3.00 ng/kg/min.

19. (*New*) The method of claim 5 wherein glucagon is administered daily at bedtime.

20. (*New*) The method of claim 5 wherein the patient has a has a blood glucose level that is not less than 50 mg/dL.

21. (*New*) A method of reducing the risk of insulin-induced hypoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering glucagon to the patient as part of a diabetes treatment regimen, wherein glucagon is administered daily at bedtime, wherein said patient is not suffering hypoglycemic symptoms.

22. (*New*) The method of claim 21 wherein the patient has a blood glucose level of from 70 - 110 mg/dL.

23. (*New*) The method of claim 21 wherein the patient has a has a blood glucose level that is not less than 50 mg/dL.

24. (*New*) The method of claim 21 in which a dose of glucagon is administered that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kg/min.

25. (*New*) The method of claim 24 in which a dose of glucagon is administered that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 3.00 ng/kg/min.